USPTO serial 88830833
TRIVAIR
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- ROTH, BENJAMIN H.
- Law office
- TMO LAW OFFICE 122
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with TRIVAIR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Mississauga, Ontario, CA
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Darrell G. Mottley
Darrell G. Mottley Banner & Witcoff, Ltd.1100 13th Street, N.W., 12th FloorWashington, DC 20005United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Inhalers filled with pharmaceutical preparations for use in the treatment of respiratory diseases, disorders and infections; inhalers filled with pharmaceutical preparations for use in the treatment of asthma; inhalers filled with pharmaceutical preparations for use in the treatment of chronic obstructive pulmonary disease; inhalers filled with pharmaceutical preparations for use in the treatment of rhinitis; inhalers filled with pharmaceutical preparations for use in the treatment of sinus polyps; inhalers filled with pharmaceutical preparations for use in the treatment of viral airway infections; inhalers filled with pharmaceutical preparations for use in the treatment of multiple sclerosis; inhalers filled with pharmaceutical preparations for use in the treatment of depression; inhalers filled with pharmaceutical preparations for use in the treatment of epilepsy; inhalers filled with pharmaceutical preparations for use in the treatment of migraine; inhalers filled with pharmaceutical preparations for use in the treatment of Alzheimer's disease; inhalers filled with pharmaceutical preparations for use in the treatment of Parkinson's disease; inhalers filled with pharmaceutical preparations for use in the treatment of cerebrovascular accident or stroke; inhalers filled with pharmaceutical preparations for use in the treatment of traumatic brain injury; inhalers filled with pharmaceutical preparations for use in the treatment of cancer; inhalers filled with pharmaceutical preparations for use in the treatment of nausea; inhalers filled with pharmaceutical preparations for use in the treatment of post-traumatic stress disorder; inhalers filled with pharmaceutical preparations for use in the treatment of amyotrophic lateral sclerosis; inhalers filled with pharmaceutical preparations for use in the treatment of chronic pain; inhalers filled with pharmaceutical preparations for use in the treatment of insomnia; inhalers filled with pharmaceutical preparations for use in the relief of pain; inhalers filled with pharmaceutical preparations for use in the treatment of cough or sore throat; inhalers filled with pharmaceutical preparations for use in the treatment of candida infection; inhalers filled with pharmaceutical preparations for use in anti-fungal treatment; inhalers filled with pharmaceutical preparations for use in sedation; inhalers filled with pharmaceutical preparations for use in hormone replacement therapy; inhalers filled with pharmaceutical preparations for use in the treatment of psychosis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of respiratory diseases, disorders and infections; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of asthma; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of chronic obstructive pulmonary disease; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of rhinitis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of sinus polyps; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of viral airway infections; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of multiple sclerosis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of depression; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of epilepsy; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of migraine; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of Alzheimer's disease; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of Parkinson's disease; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of cerebrovascular accident or stroke; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of traumatic brain injury; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of cancer; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of nausea; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of post-traumatic stress disorder; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of amyotrophic lateral sclerosis; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of chronic pain; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of insomnia; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the relief of pain; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of cough or sore throat; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of candida infection; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in anti-fungal treatment; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in sedation; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in hormone replacement therapy; drug delivery devices, namely, breath actuated nasal delivery devices filled with pharmaceutical preparations for use in the treatment of psychosis; inhalers used to deliver therapeutic agents, namely, analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, or antipsychotics; drug delivery devices, namely, breath actuated nasal delivery devices used to deliver therapeutic agents, namely, analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, or antipsychotics; inhalers filled with analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, respiratory therapeutic agents, or antipsychotics; drug delivery devices, namely, breath actuated nasal delivery devices filled with analgesics, sedatives, vaccines, anesthetics, insulin, antiemetics, antifungals, hormones, respiratory therapeutic agents, or antipsychotics; none of the foregoing containing cannabis or CBD | ACTIVE | — |
| 010 | Medical apparatus and instruments, namely, inhalers, sold empty, for therapeutic use; medical apparatus and instruments, namely, breath actuated nasal drug delivery devices, sold empty, for therapeutic use; none of the foregoing for use with cannabis or CBD | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 30, 2026 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Apr 30, 2026 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jan 14, 2026 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Jan 14, 2026 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Jan 14, 2026 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Sep 17, 2025 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Mar 16, 2025 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Mar 16, 2025 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Mar 16, 2025 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Mar 14, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 14, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Mar 14, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 13, 2025 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Dec 27, 2024 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Dec 27, 2024 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Dec 27, 2024 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Feb 7, 2024 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Feb 7, 2024 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Feb 7, 2024 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Feb 2, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 30, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 30, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 30, 2024 | ALIE | ASSIGNED TO LIE | — |
| May 15, 2023 | ERSI | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED | — |
| Nov 15, 2022 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Nov 15, 2022 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Nov 15, 2022 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Oct 28, 2022 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Oct 28, 2022 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Oct 28, 2022 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 28, 2022 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| May 18, 2022 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| May 18, 2022 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| May 18, 2022 | CNSL | SUSPENSION LETTER WRITTEN | — |
| May 18, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 18, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 11, 2022 | ALIE | ASSIGNED TO LIE | — |
| May 10, 2022 | NREV | NOTICE OF REVIVAL - E-MAILED | — |
| May 9, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 9, 2022 | PETG | PETITION TO REVIVE-GRANTED | — |
| May 9, 2022 | PROA | TEAS PETITION TO REVIVE RECEIVED | — |
| May 3, 2022 | MAB2 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 3, 2022 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 3, 2022 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 3, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 5, 2021 | GNS2 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED | — |
| Oct 5, 2021 | GNSI | INQUIRY TO SUSPENSION E-MAILED | — |
| Oct 5, 2021 | CNSI | SUSPENSION INQUIRY WRITTEN | — |
| Sep 1, 2021 | RCCK | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION | — |
| Jan 8, 2021 | GNS3 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED | — |
| Jan 8, 2021 | GNSL | LETTER OF SUSPENSION E-MAILED | — |
| Jan 8, 2021 | CNSL | SUSPENSION LETTER WRITTEN | — |
| Jan 5, 2021 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 5, 2021 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 5, 2021 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 5, 2021 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Sep 14, 2020 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 14, 2020 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 14, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 14, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 17, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 2, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 18, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 14, 2020 | NWAP | NEW APPLICATION ENTERED | — |